NewAmsterdam Pharma Co N.V. 8-K

What Happened
NewAmsterdam Pharma Co N.V. announced via Form 8-K (filed March 2, 2026) that it posted an updated corporate investor presentation on its website. The disclosure was made under Item 7.01 (Regulation FD Disclosure) and the presentation is furnished as Exhibit 99.1 to the Current Report.

Key Details

• Date filed: March 2, 2026 (Form 8-K).
• Item reported: 7.01 Regulation FD Disclosure; Exhibit 99.1 is the March 2, 2026 corporate presentation.
• Website: presentation posted at https://www.newamsterdampharma.com.
• Signature: report signed by Ian Somaiya, Chief Financial Officer.

Why It Matters
This 8-K signals that NewAmsterdam shared updated corporate materials broadly with investors (Regulation FD). The presentation may contain the company’s latest strategic, clinical or corporate updates; investors and analysts should review Exhibit 99.1 on the company site for details. Note the company states content on its website is not incorporated into the 8-K.